中国药房2026，Vol.37Issue(6)：708-712,5.DOI:10.6039/j.issn.1001-0408.2026.06.03
4种治疗高脂血症中成药的临床综合评价
Clinical comprehensive evaluation of four Chinese patent medicines in the treatment of hyperlipidemia
摘要
Abstract
OBJECTIVE To evaluate the clinical comprehensive value of four Chinese patent medicines(Xuezhikang,Zhibitai,Zhibituo,Jiangzhiling)in the treatment of hyperlipidemia,and provide a reference for rational clinical drug use.METHODS A clinical comprehensive evaluation index system was established in accordance with the Evidence and Value:Impact on Decision-Making(EVIDEM)framework and Technical Guideline for Clinical Comprehensive Evaluation of Cardiovascular Drugs(2022 edition,trial implementation).CNKI,Wanfang data,VIP,PubMed,ScienceDirect,Embase and official websites were retrieved to collect the literature such as drug instructions,guidelines and consensus statements,and systematic reviews/meta-analyses for the four Chinese patent medicines.A comprehensive evaluation was conducted from seven dimensions:effectiveness,safety,economy,suitability,accessibility,innovation and characteristics of traditional Chinese medicine.RESULTS This evaluation index system included 7 first-level indicators,15 second-level indicators and 30 third-level indicators.Xuezhikang achieved the highest comprehensive evaluation score of 81.4 points,and was classified as class Ⅰ recommendation.Zhibitai with 76.0 points and Zhibituo with 60.9 points were both classified as class Ⅱ recommendation.Jiangzhiling with 48.8 points was classified as class Ⅳ recommendation.CONCLUSIONS Xuezhikang demonstrates the optimal clinical comprehensive value for treating hyperlipidemia.Zhibitai exhibits certain advantages in terms of safety and characteristics of traditional Chinese medicine;Zhibituo shows a moderate performance in all aspects;Jiangzhiling has a relatively low score.Appropriate medicines can be selected clinically according to actual conditions and patients'characteristics.关键词
高脂血症/中成药/临床综合评价/血脂康/脂必泰/脂必妥/降脂灵Key words
hyperlipidemia/Chinese patent medicine/clinical comprehensive evaluation/Xuezhikang/Zhibitai/Zhibituo/Jiangzhiling分类
医药卫生引用本文复制引用
张明珠,秦一卓,唐显帅,郑磊,宋金方..4种治疗高脂血症中成药的临床综合评价[J].中国药房,2026,37(6):708-712,5.基金项目
山东省自然科学基金面上项目(No.ZR2022MH250) （No.ZR2022MH250）
山东省医药卫生科技项目(保健项目)(No.2023BJ000001) （保健项目）
山东中医药学会临床药学科研专项基金项目(No.SDACM202207) （No.SDACM202207）
